Glycosphingolipid (GSL) (GSL)

Glycosphingolipids (GSLs) are a diverse class of membrane lipids composed of a hydrophobic ceramide tail and a hydrophilic glycan head group [1]. They are primarily located on the outer leaflet of the plasma membrane, where they organize into microdomains known as lipid rafts to facilitate signal transduction and cell-cell communication [2]. GSLs are critical for various physiological processes, including neural development and immune response modulation [1]. Pathologically, the accumulation of GSLs due to genetic deficiencies in lysosomal hydrolases leads to lysosomal storage diseases such as Gaucher and Fabry disease [3]. In oncology, certain GSLs like the ganglioside GD2 are overexpressed on the surface of neuroblastoma and melanoma cells, serving as specific targets for immunotherapy [4]. Therapeutic interventions include substrate reduction therapies (SRTs) like eliglustat, which inhibit GSL synthesis, and monoclonal antibodies like dinutuximab, which target tumor-associated GSLs [3,4].

Other names

Plasma membrane glycosylated ceramidesGlycosylceramideGlycosylated ceramideNeutral glycosphingolipidAcidic glycosphingolipidGangliosideGloboside

Inhibition of glucosylceramide synthase (UGCG) to decrease the production of glycosphingolipids (substrate reduction therapy) or direct binding of monoclonal antibodies to tumor-associated surface gangliosides to induce immune-mediated cytotoxicity.